Related Experiment Video
Updated: May 8, 2026

08:54
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
Published on: May 19, 2020
Development of the Drug Adherence Work-up (DRAW) tool
Journal of the American Pharmacists Association : Japha
|August 16, 2013
Summary
The Drug Adherence Work-up (DRAW) tool helps pharmacists improve medication therapy management (MTM) visits by identifying multiple reasons for nonadherence, such as side effects or forgetfulness.
Area of Science:
- Pharmacy practice
- Medication adherence research
- Patient counseling
Background:
- Medication nonadherence is a significant challenge in healthcare.
- Pharmacists play a crucial role in addressing nonadherence during medication therapy management (MTM).
- Existing tools may not comprehensively address the multifaceted nature of nonadherence.
Purpose of the Study:
- To develop and conduct an initial field test of the Drug Adherence Work-up (DRAW) tool.
- To evaluate DRAW's utility in guiding pharmacists during MTM visits for nonadherent patients.
- To gather pharmacist feedback on the usability and effectiveness of the DRAW tool.
Main Methods:
- Prospective cohort study involving seven trained pharmacists.
- Pharmacists used the DRAW tool during MTM visits with patients identified as potentially nonadherent.
- Data collected through MTM claims and an online survey of pharmacist opinions.
Main Results:
- Pharmacists reported DRAW improved MTM service focus and adherence problem resolution.
- The DRAW tool was perceived as easy to use and well-organized.
- Most common nonadherence reasons: adverse effects (59.1%) and forgetting (54.5%); 77.3% of patients had multiple reasons.
Conclusions:
- The DRAW tool may assist pharmacists in addressing diverse reasons for medication nonadherence.
- DRAW's comprehensive nature is beneficial for tackling multifaceted nonadherence.
- Further research is warranted to validate and refine the DRAW tool.
Related Concept Videos
Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Dosage Regimens: Designs and Approaches
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
In Vitro Drug Release Testing: Overview, Development and Validation
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
